Investigating gut microbiota and genetics in inflammatory bowel diseases
Investigating the Intestinal Microbiota, Epigenetic Markers and Body Fluid Metabolites to Identify Biomarkers for Inflammatory Bowel Diseases
Chinese University of Hong Kong · NCT03855657
This study is trying to understand how gut bacteria and genetics affect inflammatory bowel diseases like ulcerative colitis and Crohn's disease, to help improve treatment for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese University of Hong Kong (other) |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT03855657 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a large-scale biobank to investigate the gut microbiota, genetics, epigenetics, and metabolites associated with inflammatory bowel diseases (IBD), specifically ulcerative colitis and Crohn's disease. It addresses the rising incidence of IBD in Asia and seeks to understand the interplay between genetic predisposition and environmental factors in disease development. By collecting comprehensive clinical data from patients, the study aims to personalize therapy and improve treatment outcomes for IBD patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with Crohn's disease or ulcerative colitis.
Not a fit: Patients with known current infections or those with a family history of IBD may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with inflammatory bowel diseases.
How similar studies have performed: Other studies have shown success in utilizing biobanks to investigate complex diseases, suggesting that this approach could yield valuable insights into IBD.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient ≥18 with a diagnosis of Crohn's disease or ulcerative colitis * Informed Consent obtained Exclusion Criteria: * Known current infection with an enteric pathogen * Previously been diagnosed with IBD (Control) * Have a first of second degree relative with IBD (Control)
Where this trial is running
Hong Kong
- Prince of Wales Hospital — Hong Kong, Hong Kong (RECRUITING)
Study contacts
- Principal investigator: Siew Chien Ng, PhD — Chinese University of Hong Kong
- Study coordinator: Siew Chien Ng, PhD
- Email: siewchienng@cuhk.edu.hk
- Phone: 852-35053996
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Inflammatory Bowel Diseases, Biobank